Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Rash Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel

NCT01844739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NVN1000 4% Gel, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

NCT00599521
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene lotion 0.1%, Adapalene Lotion Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
San Diego, California • Vista, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of S6G5T3 in the Treatment of Acne Vulgaris

NCT03761810
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

NCT04300296
View directory record Official record
Conditions
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Interventions
secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 31, 2026, 2:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

NCT07544251
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sarecycline, Doxycycline
Drug
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
9 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 31, 2026, 2:53 AM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Early Phase 1 Interventional

Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

NCT05030415
View directory record Official record
Conditions
Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris
Interventions
Ixekizumab Auto-Injector
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Acleara Needle Insert on Acne

NCT01677221
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acleara Acne Treatment System
Device
Lead sponsor
Theravant Corporation
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
White Plains, Maryland • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 31, 2026, 2:53 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris

NCT01193764
View directory record Official record
Conditions
Acne
Interventions
100% cocoa powder, gelatin (Gelita)
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 31, 2026, 2:53 AM EDT
Not yet recruiting Not applicable Interventional

Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

NCT06729450
View directory record Official record
Conditions
Acne Vulgaris on the Face
Interventions
DispersinB Acne Cleanser
Device
Lead sponsor
Kane Biotech Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

NCT00664248
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-110, Clindamycin, Benzoyl peroxide, Vehicle
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
12 Years to 70 Years
Enrollment
1,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
33
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02556788
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 (trifarotene) 50µg/g Cream, Placebo Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
1,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris

NCT02515305
View directory record Official record
Conditions
Acne
Interventions
Clindamycin and Benzoyl Peroxide Gel (combination), Clindamycin and Benzoyl Peroxide Gel (Reference) (combination), Placebo gel (combination)
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Weekly Isotretinoin Therapy Study

NCT04594759
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris

NCT02604680
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100-1, BLI1100-2, BLI1100-3, BLI1100-4, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fractional Resurfacing Device for Treatment of Acne Scarring

NCT00585286
View directory record Official record
Conditions
Acne, Scar
Interventions
10,600 nm fractional carbon dioxide laser system
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 31, 2026, 2:53 AM EDT
Terminated No phase listed Observational

Investigation of Southern Tick-Associated Rash Illness (STARI)

NCT00358761
View directory record Official record
Conditions
Southern Tick-Associated Rash Illness
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 31, 2026, 2:53 AM EDT
Terminated Not applicable Interventional

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

NCT00767689
View directory record Official record
Conditions
Hand and Foot Syndrome
Interventions
Vitamin B 6, placebo
Drug
Lead sponsor
Cook County Health
Government
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

NCT01931150
View directory record Official record
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Not applicable Interventional

Evaluation and Treatment of Oral Soft Tissue Diseases

NCT00001601
View directory record Official record
Conditions
Aphthous Stomatitis, Burning Mouth Syndrome, Lichen Planus, Mouth Disease, Temporomandibular Joint Disorder
Interventions
Electrocardiogram, Biopsies, Diagnostic imaging
Procedure
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

NCT00691769
View directory record Official record
Conditions
Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
30 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 31, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03127956
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil Gel, 5.0%
Drug
Lead sponsor
Dermira, Inc.
Industry
Eligibility
9 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
73
States / cities
Guntersville, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 31, 2026, 2:53 AM EDT